Heparin Market to grow by USD 3.01 billion from 2022 to 2027, Europe to account for 39% of market growth- Technavio

NEW YORK, Sept. 10, 2023 /PRNewswire/ -- The heparin market size is expected to grow by USD 3.01 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of  6.94% during the forecast period, according to Technavio Research. The market has segmented by Product (Low-molecular-weight heparin and Others), Route of Administration (Subcutaneous injection, and Intravenous/infusion), and Geography (Europe, North America, Asia, and Rest of World (ROW)). Europe is estimated to account for 39% of the global market during the forecast period.  In 2022, Europe emerged as the dominant player in the global heparin market, with the United Kingdom, Germany, and France taking the lead within the region. This prominence is attributed to several factors, including the rising rates of obesity, smoking, and high alcohol consumption prevalent in Europe. Moreover, the growing number of surgical procedures performed in the region has also contributed to market expansion. Additionally, Europe faces a notable incidence of pulmonary embolism and deep vein thrombosis (DVT) following hip or knee replacement surgeries, as highlighted by the Organisation for Economic Co-operation and Development (OECD). This heightened prevalence of deep vein thrombosis and pulmonary embolism has led to increased adoption of heparin, which in turn drives the market growth in the region during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report

Company Profile:

Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, and Sanofi SA.

Aspen Pharmacare Holdings - The company offers heparin namely Orgaran.

   To gain access to more vendor profiles available with Technavio, buy the report!

Heparin Market: Segmentation Analysis

The market has been segmented by Product (Low-molecular-weight heparin and Others), Route of Administration (Subcutaneous injection, and Intravenous/infusion), and Geography (Europe, North America, Asia, and Rest of World (ROW)).

• The market share growth by the low-molecular-weight heparin segment will be significant during the forecast period. Low-molecular-weight heparin functions by impeding the blood coagulation process, whereby it facilitates the conversion of fibrinogen to fibrin via thrombin activity. This inhibition of coagulation occurs as low-molecular-weight heparin activates antithrombin III, which, in turn, binds to and hinders factor Xa. Consequently, it obstructs the activation of factor Xa, preventing the conversion of prothrombin into thrombin, and thereby, the transformation of fibrinogen into fibrin for blood clot formation.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

Heparin Market: Driver & Trend:

The increased prevalence of chronic conditions is one of the key factors that will fuel the heparin market. The prevalence of chronic conditions like cardiovascular diseases, kidney diseases, and inflammatory disorders is on the rise, primarily due to risk factors such as obesity, insufficient physical activity, unhealthy dietary habits, excessive alcohol consumption, and smoking. Notably, it is projected that 25% of the US population will be severely obese by 2030. Additionally, there is a significant global increase in the occurrence of various coagulation disorders, including Von Willebrand disease, haemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies. This growing prevalence of coagulation disorders necessitates ongoing monitoring for potential medical interventions, consequently fueling the expansion of the global heparin market. Such factors are expected to drive the market growth during the forecast period.  Identify key trends, drivers, and challenges in the market. Download sample to gain access to this information.

What are the key data covered in this heparin market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the heparin market between 2022 and 2027.
• Precise estimation of the heparin market size and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of heparin market vendors.

Related Reports:

The Global Anticoagulants Market size is estimated to grow at a CAGR of 8.42% between 2022 and 2027. The market size is forecast to increase by USD 18,091.94 million. This report extensively covers market segmentation by route of administration (oral anticoagulants and injectable anticoagulants), type (Factor Xa inhibitors, DTIs, Heparin, and Vitamin K antagonists), and geography (North America, Europe, Asia, and Rest of World (ROW)). The increase in hip and knee surgeries is notably driving the global anticoagulants market growth. 

The anti-thrombin III testing market share is expected to increase to USD 161.48 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.73%. This report extensively covers anti-thrombin III testing market segmentation by end-user (hospitals, laboratories, and academic and research institutes) and geography (North America, Europe, Asia, and Rest of World (ROW)). One of the key factors driving the global anti-thrombin III testing market growth is the existence of tests for patients with anti-thrombin deficiency.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Product

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio